Zoledronic acid and angiogenesis [1]

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6850-

  Ferretti, Gianluigi ^a   Fabi, Alessandra ^a   Carlini, Paolo ^a   Papaldo, Paola ^a   Felici, Alessandra ^a   Tomao, Silverio ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; GELATINASE B; STEM CELL FACTOR; VASCULOTROPIN; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD LEVEL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFER; DRUG ACCUMULATION; DRUG INHIBITION; DRUG INTERMITTENT THERAPY; HEMATOPOIETIC STEM CELL; INTRACELLULAR MEMBRANE; LETTER; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TARGET CELL;

EID: 36749074499     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4036     Document Type: Letter

References (5)

1. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007;13:4482-6.
2. Ferretti G, Fabi A, Carlini P, Papaldo P, Felici A, Cognetti F. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. Bone 2007;41:155-6.
3. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114:623-33.
4. Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4.
5. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-37.